KA Imaging Announces New Funding for Its Activities

X-ray manufacturer KA Imaging announced today new funding for its activities. Both new investments focus on the Reveal™ 35C detector. In-Q-Tel, Inc. and INOVAIT are now part of the strong list of partners working with KA Imaging.

Spectral Imaging in the Emergency Department

One of the projects, “Single exposure Dual Energy Subtraction X-ray Device for Image Guided Therapy”, aims to use the Reveal 35C in the Emergency Room. KA Imaging, in partnership with Sunnybrook Research Institute, will obtain X-ray images from patients, and use it to develop new material separation imaging algorithms for real-time image-guided therapy applications.

Funding for this project was provided in part by INOVAIT through the Government of Canada’s Strategic Innovation Fund.

“We’re proposing a widely accessible and affordable solution to achieve improved soft tissue, bone and foreign object visibility, without added acquisition time or patient imaging dose,” explained Karim S. Karim, CTO of KA Imaging.

INOVAIT is a pan-Canadian network funded by the Government of Canada and hosted at the Sunnybrook Research Institute with the objective of building a truly integrated image-guided therapy ecosystem, fueling continuous innovation that revolutionizes healthcare globally. Through connecting, educating, and investing in the industry’s brightest minds and most promising ventures, INOVAIT will support and encourage collaborative development and the integration of artificial intelligence (AI) into medical technologies.

Accelerating innovation

KA Imaging has also signed a strategic investment and technology development agreement with In-Q-Tel, the not-for-profit strategic investor that accelerates the development and delivery of cutting-edge technologies to the U.S. intelligence and national security community and its allies.

“KA Imaging’s patented technology benefits application areas ranging from healthcare to non-destructive testing. Reveal’s unique energy subtraction capabilities and portability make it a solution that can be effectively and easily deployed in challenging environments,” said Michael Falcon, Investment Partner at In-Q-Tel.

“We are pleased to be part of the In-Q-Tel portfolio and look forward to expanding our relationship with IQT and its government partners”, said Amol Karnick, President and CEO of KA Imaging.

About Reveal 35C

Reveal™ 35C is a single exposure, portable, digital dual-energy subtraction (DES) X-ray detector. Powered by its exclusive SpectralDR™technology, it uses the same radiation dose as a traditional X-ray to create 3 different images without motion artifacts. In medical applications, this means a regular DR, plus a soft tissue and bone images. In the NDT market, Reveal’s energy subtraction capabilities can be translated into material differentiation, such as metals and plastics.

 

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.